oxybutynin has been researched along with Cardiovascular Diseases in 8 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Randomised controlled trials and meta-analyses have demonstrated that single therapy with either NRT, bupropion or varenicline are all more effective than placebo for smoking cessation." | 4.86 | Smoking cessation-recent advances. ( Ioannides-Demos, LL; McNeil, JJ; Piccenna, L, 2010) |
| "In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events." | 3.30 | Cardiovascular Safety of Testosterone-Replacement Therapy. ( Basaria, S; Bhasin, S; Boden, WE; Chan, A; Cunningham, GR; Davey, D; Dubcenco, E; Flevaris, P; Granger, CB; Huang, B; Kalahasti, V; Khan, N; Khera, M; Li, X; Lincoff, AM; Miller, MG; Mitchell, LM; Nissen, SE; Pencina, KM; Snabes, MC; Thompson, IM; Travison, TG; Wang, Q; Wolski, K; Yi, T, 2023) |
| "Increases in testosterone use and mixed reports of adverse events have raised concerns about the cardiovascular safety of testosterone." | 1.42 | Comparative Safety of Testosterone Dosage Forms. ( Brookhart, MA; Jick, SS; Layton, JB; Meier, CR; Sharpless, JL; Stürmer, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Laustsen, G | 1 |
| Wimett, L | 1 |
| Lincoff, AM | 1 |
| Bhasin, S | 1 |
| Flevaris, P | 1 |
| Mitchell, LM | 1 |
| Basaria, S | 1 |
| Boden, WE | 1 |
| Cunningham, GR | 1 |
| Granger, CB | 1 |
| Khera, M | 1 |
| Thompson, IM | 1 |
| Wang, Q | 1 |
| Wolski, K | 1 |
| Davey, D | 1 |
| Kalahasti, V | 1 |
| Khan, N | 1 |
| Miller, MG | 1 |
| Snabes, MC | 1 |
| Chan, A | 1 |
| Dubcenco, E | 1 |
| Li, X | 1 |
| Yi, T | 1 |
| Huang, B | 1 |
| Pencina, KM | 1 |
| Travison, TG | 1 |
| Nissen, SE | 1 |
| Bezwada, P | 1 |
| Shaikh, A | 1 |
| Misra, D | 1 |
| van Velzen, DM | 1 |
| Paldino, A | 1 |
| Klaver, M | 1 |
| Nota, NM | 1 |
| Defreyne, J | 1 |
| Hovingh, GK | 1 |
| Thijs, A | 1 |
| Simsek, S | 1 |
| T'Sjoen, G | 1 |
| den Heijer, M | 1 |
| Layton, JB | 1 |
| Meier, CR | 1 |
| Sharpless, JL | 1 |
| Stürmer, T | 1 |
| Jick, SS | 1 |
| Brookhart, MA | 1 |
| McNeil, JJ | 1 |
| Piccenna, L | 1 |
| Ioannides-Demos, LL | 1 |
| Berlin, I | 1 |
| Jacob, N | 1 |
| Coudert, M | 1 |
| Perriot, J | 1 |
| Schultz, L | 1 |
| Rodon, N | 1 |
| Połać, I | 1 |
| Borowiecka, M | 1 |
| Wilamowska, A | 1 |
| Nowak, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does Dose Adjustment of Nicotine Replacement Therapies According to Saliva Cotinine Increase Efficacy of These Treatments of Assistance To the Nicotinic Weaning Of the High-Risk Patients?[NCT00235313] | Phase 4 | 300 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for oxybutynin and Cardiovascular Diseases
| Article | Year |
|---|---|
Drug approval highlights for 2003.
Topics: Acyclovir; Cardiovascular Agents; Cardiovascular Diseases; Dermatologic Agents; Drug Approval; Estro | 2004 |
The Effect of Transdermal Estrogen Patch Use on Cardiovascular Outcomes: A Systematic Review.
Topics: Administration, Cutaneous; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens; Female; | 2017 |
Smoking cessation-recent advances.
Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therap | 2010 |
3 trials available for oxybutynin and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Safety of Testosterone-Replacement Therapy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Ge | 2023 |
Adjustment of nicotine replacement therapies according to saliva cotinine concentration: the ADONIS* trial-a randomized study in smokers with medical comorbidities.
Topics: Administration, Buccal; Cardiovascular Diseases; Comorbidity; Cotinine; Counseling; Diabetes Mellitu | 2011 |
Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Topics: Administration, Oral; Blood Coagulation; Cardiovascular Diseases; Drug Combinations; Dydrogesterone; | 2013 |
2 other studies available for oxybutynin and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen.
Topics: Administration, Oral; Adolescent; Adult; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; | 2019 |
Comparative Safety of Testosterone Dosage Forms.
Topics: Administration, Cutaneous; Adult; Aged; Androgens; Cardiovascular Diseases; Gels; Humans; Injections | 2015 |